Amgen's Dazodalibep Shines in Late-Stage Sjogren's Disease Trial
Amgen's experimental drug dazodalibep has shown statistically significant and clinically meaningful improvement in patients with Sjogren's disease, according to a late-stage trial. The disease affects about 1% of the global population, predominantly women, causing dryness of the eyes, mouth, and other parts of the body, along with fatigue and chronic pain.
The trial met its main goal of reducing disease activity in patients with moderate-to-severe Sjogren's disease at week 48. Amgen said most adverse events were mild to moderate, with few patients discontinuing treatment. Analyst Matt Phipps noted the trial results were encouraging given the drug's high risk and development challenges.
Novartis and Johnson & Johnson are also developing drugs for Sjogren's disease, which currently has no approved treatments in the US. Amgen plans to present detailed data from the trial at an upcoming medical meeting and is testing the drug in a separate trial with results expected in the fourth quarter of 2026.